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Background
A limiting step for adoptively transferred tumour-specific
T cells is their recruitment from the blood circulation to
the proximity of tumour cells and subsequent engage-
ment in direct tumour cell contact. We hypothesised that
a bispecific antibody recruiting T cells to a target antigen
on tumour cells could enhance T-cell-tumour interaction
and thus increase the efficacy of adoptively transferred
T cells.
Material and methods
A new bispecific murine IgG2a antibody (BsAb) was gen-
erated that recognises EpCAM as a tumour antigen and
truncated EGFR (D-EGFR) as an inert surface marker pro-
tein on transduced T cells. T cells from transgenic mice
for TCR specific for the SV40 large T antigen (TCR-1)
were retrovirally transduced with D-EGFR. S.c. tumors
were induced in C57Bl/6 mice by injecting mGC8 cells
derived from a syngeneic large T antigen expressing
EpCAM-positive gastric tumor.
Results
In vitro, the BsAb increased (4-fold) binding of trans-
duced T cells to EpCAM positive tumour cells. In the
presence of the BsAb, tumour-directed T cells efficiently
lysed EpCAM-positive cells (83 % at a 10:1 effector to
target ratio). In vivo, the antibody reached EpCAM+
tumour cells as evidenced by immunofluorescence.
mGC8 tumour-bearing mice were treated twice with a
combination of the BsAb and transduced TCR-I T cells.
Tumour growth was significantly reduced for over
30 days (n=12) compared with control groups (trans-
duced T-cells or BsAb alone) and survival was prolonged
by > 30 days (p<0.001).
Conclusions
Co-administration of a BsAb bridging adoptively trans-
ferred tumour-specific T cells via an inert surface mole-
cule to a tumour-associated surface antigen enhances
the efficacy of therapeutic T cell transfer.
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